WT1 Gene Expression in Ovarian Cancer
Author Information
Author(s): Netinatsunthorn Wirote, Hanprasertpong Jitti, Dechsukhum Chavaboon, Leetanaporn Roengsak, Geater Alan
Primary Institution: Prince of Songkla University
Hypothesis
The study aims to determine the survival and recurrence-free survival of women with advanced serous epithelial ovarian carcinoma in relation to WT1 gene expression.
Conclusion
The expression of the WT1 gene may indicate an unfavorable prognosis in patients with advanced serous epithelial ovarian carcinoma.
Supporting Evidence
- Fifty patients showed WT1 staining and forty-nine did not.
- Five-year survival of non-staining and staining groups were 39.4% and 10.7%, respectively.
- Five-year recurrence-free survival of these groups were 29.8% and ≤ 7.5%, respectively.
Takeaway
This study found that women with a specific gene expression (WT1) have a worse chance of surviving ovarian cancer.
Methodology
The study reviewed medical records and performed immunohistochemical staining on tissue samples from patients diagnosed with advanced serous epithelial ovarian carcinoma.
Limitations
The study is limited by its retrospective design and the small number of stage IV patients.
Participant Demographics
Mean age at diagnosis was 54.53 years, with most patients in FIGO stage III.
Statistical Information
P-Value
p < 0.00005
Confidence Interval
95% CI 1.28–3.79 for overall survival; 95% CI 1.60–7.03 for recurrence-free survival.
Statistical Significance
p<0.00005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website